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Abstract 
HLA-mismatched grafts are a viable alternative source for patients without HLA-matched donors receiving 
ablative hematopoietic cell transplantation (HCT), though their use in reduced intensity or 
nonmyeloablative conditioning HCT has been not well established. Here we extended HCT to recipients of 
HLA-class I mismatched grafts to test whether nonmyeloablative conditioning can establish stable donor 
engraftment. Fifty-nine patients were conditioned with fludarabine 90 mg/m2 and 2 Gy total body 
irradiation (TBI) followed by immunosuppression with cyclosporine 5.0 mg/kg twice and mycophenolate 
mofetil 15 mg/kg three times daily for transplantation of granulocyte colony-stimulating factor-mobilized 
peripheral blood cells from related (n=5) or unrelated donors (n=54) with one antigen ± one allele HLA-class 
I mismatch or two HLA-class I allele mismatches. Sustained donor engraftment was observed in 95% of 
evaluable patients. The incidences of grades II to IV acute and extensive chronic graft-versus-host disease 
were 69% and 41%, respectively. The cumulative probability of non-relapse mortality was 47% at 2 years. 
Two-year overall and progression-free survivals were 29% and 28%, respectively. Nonmyeloablative 
conditioning with fludarabine and low-dose TBI followed by HCT using HLA-class I mismatched donors leads 
to successful engraftment and long-term survival; however, the high incidence of acute GVHD and NRM 
needs to be addressed by alternate GVHD prophylaxis regimens. 
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INTRODUCTION 
Allogeneic hematopoietic cell transplantation (HCT) from HLA-matched donors is a well established curative 
strategy for patients with hematopoietic malignancies; however, only 20–30% of patients in need of HCT 
have genotypically matched sibling donors. Although unrelated donor registries have grown enormously, 
potential donors cannot be identified for 20% of Caucasians and more than 60% of African-American 
patients. In addition, patients with rare haplotypes are unlikely to find HLA-matched unrelated donors in a 
timely fashion. There is a need for a suitable transplantation procedure that can extend the application of 
HCT with reduced intensity or nonmyeloablative conditioning to patients who have no readily available 
HLA-matched donor. Alternative sources including HLA-mismatched unrelated donor for HCT have been 
explored to extend the pool of donors [1,2]. 
The use of HLA-class I mismatched unrelated donors is associated with an increased risk of graft rejection in 
the myeloablative setting [3–5]. In addition, the intensity of conditioning for HCT is also associated with 
successful engraftment. Thus, the risk of graft rejection may increase in the HLA-mismatched 
nonmyeloablative setting compared to the myeloablative setting due to less intensive conditioning. It is not 
known what degree of mismatch would lead to unacceptable levels of rejection for patients receiving 
nonmyeloablative HCT. 
 
Based on preclinical studies [6], we have successfully applied a nonmyeloablative conditioning regimen 
involving fludarabine 90 mg/m2, 2 Gy total body irradiation (TBI), and post-grafting immunosuppression 
with mycophenolate mofetil (MMF) and cyclosporine (CSP) as conditioning for grafts from either HLA-
matched related or unrelated donors in more than 1200 patients who were ineligible for high-dose HCT 
because of advanced age or co-morbidities [7–12]. Here, in this multi-center phase I/II trial, we extended 
nonmyeloablative HCT to include recipients of related or unrelated G-CSF mobilized peripheral blood stem 
cell (PBSC) grafts from donors who were mismatched for one HLA-class I antigen with or without one allele 
level HLA-class I mismatches, or donors who were mismatched for two HLA-class I alleles. In addition, we 
evaluated immune reconstitution after HCT in a subset of the unrelated recipients. 
PATIENTS, MATERIALS, AND METHODS 
 
This phase I/II multi-center trial included seven transplant centers: Fred Hutchinson Cancer Research 
Center (FHCRC), University of Utah, University of Torino, Italy, Medical College of Wisconsin, LDS Hospital, 
Rocky Mountain Cancer Center and Veterans Affairs Puget Sound Health Care System, Seattle, with the 
FHCRC acting as the coordinating center. The protocol was approved by the Institutional Review Boards of 
the FHCRC and each of the collaborating performance sites. Written informed consent was obtained from 
all patients. 
Study endpoints 
 
The primary objective of this trial was to determine whether stable allogeneic engraftment from related 
and unrelated HLA-mismatched PBSC donors could be safely established using the nonmyeloablative 
fludarabine/2Gy TBI conditioning regimen with or without escalating doses of the anti-CD52 monoclonal 
antibody, alemtuzumab, in patients with hematological malignancies. Secondary objectives included 
evaluation of: 1) acute and chronic GVHD, 2) infections, 3) disease progression and relapse, and 4) 
immunological reconstitution. 
Eligibility criteria 
 
Patients enrolled on this study were ineligible for conventional HCT and had disease expected to be stable 
for at least 100 days without further chemotherapy. Forty-one patients were more than 50 years old. 
Eighteen patients 50 years old or less met the eligibility criteria either because of previous HCT (autologous, 
n=14; allogeneic, n=1), neurological toxicity (n=1), fungal infection and a history of major toxicity to 
chemotherapy (n=1), or pancytopenia for 3 months (n=1). 
 
Histocompatibility testing for donor selection was performed for all patients and donors, using previously 
described methods [13–15]. HLA-A, B, C, DRB1 and DQB1 alleles were typed prospectively by 
oligonucleotide hybridization or by DNA sequencing methods [16]. Compatibility of the donor with the 
recipient was tested further by lymphocyte cross-match (patient serum vs. donor T and B cells) before HCT 
[17]. Related or unrelated donors were allowed if matched for HLA-DRB1 and DQB1 alleles, and 
mismatched for a single antigen at HLA-A, -B, or -C, with or without an additional single allele mismatch at 
HLA-A, -B, or –C. Donors were excluded if the recipient was homozygous at the mismatched locus, or if 
both mismatches were at the same locus (HLA-A, -B, or -C). 
 
Patients were ineligible for the present study if they were pregnant or breast-feeding, or had rapidly 
progressive intermediate or high-grade non-Hodgkin’s lymphoma (NHL), circulating leukemic blasts in the 
peripheral blood detected by standard pathology, central nervous system involvement refractory to 
intrathecal chemotherapy, infection with the human immunodeficiency virus, active bacterial or fungal 
infection unresponsive to therapy, decompensated liver disease, corrected pulmonary diffusion capacity 
less than 35%, cardiac ejection fraction of less than 35%, poorly controlled hypertension, or a Karnofsky 
performance status less than 50%. 
Patient characteristics 
 
Fifty-nine patients were enrolled between February 2002 and October 2008 (Table 1). When classified for 
risk of relapse as previously described [18], 16, 27 and 16 patients had high, standard or low risk diseases, 
respectively. Disease status at the time of HCT included complete remission (CR) (n=29), partial remission 
(PR) (n=14), stable disease (n=4), and refractory or relapsed disease (n=12). Patients with acute myeloid 
leukemia (AML), secondary acute myeloid leukemia from myelodysplastic syndrome (MDS/AML), and acute 
lymphocytic leukemia were all in CR at the time of HCT. Four patients received planned tandem autologous 
transplant followed by nonmyeloablative HCT (auto-allo). The HCT specific comorbidity index (HCT-CI) [19] 
was available in 57 of 59 patients. Twelve patients had an HCT-CI score of 0, 21 had scores of 1 or 2, and 24 
had scores of 3 or higher. 
 HLA typing and matching 
 
Final selection of unrelated donors was based on the results of high resolution HLA typing for HLA-A, -B, -C, 
-DRB1, -DQB1 alleles (Table 1). Seven unrelated pairs and one related pair were mismatched only in the 
GVHD vector and were not considered evaluable for the rejection endpoint. Fifty-four unrelated pairs were 
mismatched for at least one antigen (19 at HLA-A, 8 at HLA-B, 26 at HLA-C) except one patient who had two 
allele mismatches (HLA-A and HLA-B). All five related pairs were mismatched for one HLA-A antigen. Ten 
patients had, in addition to the class I antigen mismatch, one allelic mismatch (two at HLA-A, four at HLA-B, 
four at HLA-C). 
Conditioning regimen and GVHD prophylaxis 
 
Patients received fludarabine (30 mg/m2/day) on days −4, −3, and −2 before HCT and 2 Gy TBI at the rate of 
0.07 Gy/minute from a linear accelerator on day 0. Postgrafting immunosuppression with oral CSP, starting 
at 5 mg/kg twice a day (BID), on day −3 and continued to day 180, then tapered to day 365. MMF was given 
orally at 15 mg/kg, based on adjusted body weight, (rounded to nearest 250 mg increment), every 8 hours 
from the evening of day 0 (4 to 6 hours after HCT infusion) and to day 100, and then tapered at 
approximately 11% weekly for 8 weeks. The taper was completed by day 156 unless GVHD occurred. When 
significant nausea or vomiting occurred during MMF treatment, MMF was administrated intravenously at 
the same dose. CSP levels were measured by immunoassay and doses were targeted to achieve trough 
levels of 500 ng/ml for the first 28 days and thereafter 150–450 ng/ml. CSP was also administrated 
intravenously in patients who were not able to take CSP orally. 
Escalation of alemtuzumab 
 
The initial study design incorporated a provision for the addition of low-dose alemtuzumab if more than 
one rejection was seen in either of the first two cohorts of 7 evaluable patients treated without 
alemtuzumab. Eleven patients were enrolled in the first cohort, of whom 7 were evaluable for the 
chimerism endpoint and all engrafted. In the second cohort, only 1 of 7 patients rejected the graft. 
Therefore, the protocol was amended to allow continued accrual without alemtuzumab. A total 59 patients 
were transplanted without alemtuzumab. 
Collection of hematopoietic cells 
 
All patients received granulocyte colony-stimulating factor (G-CSF)-mobilized PBSC grafts. All related donors 
received 16 μg/kg/day G-CSF by subcutaneous injection for 5 consecutive days before collection on days −1 
and 0. 
 
Collection of unrelated donor PBSC was arranged through the National Marrow Donor Program (NDMP) or 
international donor centers. G-CSF, 10 μg/kg, was administered by subcutaneous injection starting 5 days 
before day 0 according to the NDMP protocol. 
Supportive care 
 
All patients received standard prophylactic antibiotics with a third-generation cephalosporin or quinolone 
when absolute neutrophil counts declined to less than 500 μL. All patients received fluconazole (400 
mg/day) from the start of conditioning to at least day 75 as prophylaxis for yeast infection. Trimethoprim-
sulfamethoxazole was used as first-line prophylaxis against Pneumocystis jiroveci and dapsone (50 mg BID) 
as second line until day 180 or until discontinuation of immunosuppressive therapy. The varicella zoster 
virus prophylaxis (acyclovir 250 mg/m2 intravenously followed by 800 mg orally or valacyclovir 500 mg 
orally, BID) was performed until 1 year after HCT or 6 months after discontinuation of all 
immunosuppression. Preemptive treatment with ganciclovir was started during the first 100 days after HCT 
when CMV polymerase chain reaction or pp65 antigenemia for weekly CMV surveillance became positive. 
After day 100, surveillance and preemptive therapy were recommended for CMV intermediate and high-
risk patients on a weekly or biweekly basis. 
GVHD grading and treatment 
 
Diagnosis and clinical grading of acute and chronic GVHD were done by local investigators according to 
established criteria [20,21]. In most cases, biopsies confirmed clinical diagnosis. Treatment of acute GVHD 
was typically by administering prednisone (1–2 mg/kg/day) and reinitiating CSP at full doses if it had been 
previously tapered or discontinued. Prednisone (1 mg/kg/day) and CSP (5.0 mg/kg orally BID) were used for 
the primary treatment of extensive chronic GVHD. 
Treatment of persistent/progressive or relapsed malignancies 
 
Substantial persistent disease at day 84 or disease progression at any time was an indication for 
therapeutic intervention. If there was no GVHD, MMF was stopped and CSP was tapered over 2 weeks or 
per attending physician discretion. If there was no response to stopping immunosuppression, 
chemotherapy or radiation therapy could be considered. Donor lymphocyte infusions were not offered on 
this trial. 
Chimerism analyses 
 
Chimerism analysis of peripheral blood T cell (CD3+), granulocyte (CD33+) and whole marrow were 
performed on days +28, +56 +84, + 180, +365 and then yearly after HCT as previously described [7]. For the 
purposes of this study, full donor T-cell chimerism was defined as more than 95% donor CD3+ T cells, and 
graft rejection was defined as the inability to detect at least 5% donor CD3+ T cells, as a proportion of the 
total T cell population in the peripheral blood after HCT. Mixed or full donor chimerism was considered as 
evidence of donor engraftment. Sustained engraftment was defined as continued evidence of donor 
engraftment up to day 84 evaluation without subsequent loss at later evaluations. 
Immune reconstitution 
 
Immune reconstitution was studied in nine FHCRC recipients of HLA-class I mismatched unrelated grafts. 
Peripheral blood samples were obtained before conditioning, immediately before HCT on day 0, and at 1, 3, 
6, and 12 months after HCT. Mononuclear cells (MNCs) were separated from blood specimens, stained with 
fluorochrome-conjugated monoclonal antibodies, and analyzed by using 3-color flow cytometry as 
described [22,23]. 
 
Naive B cells were represented by IgD+ B cells, since most IgD+ B cells lack somatic mutations [24–26]. 
Naive CD4+ T cells were defined as CD45RAhigh CD4+ T cells since this subset contains thymic emigrants 
[27–29]. Naive CD8+ T cells were defined as CD11alow CD8+ T cells because virtually all cord blood CD8+ T 
cells are CD11alow and become CD11ahigh after activation [30,31]. CD28+ T cells represent cells that can 
receive both the signal mediated by the T-cell receptor and the CD28-mediated costimulatory signal. 
Monocytes were defined as CD14+ MNCs. Natural killer (NK) cells were defined as MNCs expressing CD16 
or CD56 and not expressing CD3 or CD14. Dendritic cells (DC) were defined as HLA-DRhigh MNCs not 
expressing CD3, CD14, CD16, CD20, CD34, or CD56. 
Statistical analysis 
 
Survival curves were estimated by the Kaplan-Meier method. Cumulative incidence curves for acute and 
chronic GVHD and relapse treated death as a competing risk. Cumulative incidence curves for non-relapse 
mortality treated relapse as a competing risk. Comparative analyses of mortality and competing risk 
endpoints were performed via Cox regression; all p-values reflect likelihood ratio statistics from these 
models and are 2-sided. 
RESULTS 
Engraftment, chimerism and graft rejection 
 
The median numbers of CD34+ and CD3+ cells in the grafts were 7.0 (range, 2.1–37.7) ×106 and 2.6 (range, 
0.3–6.6) ×108 cells/kg recipient body weight, respectively. The median neutrophil nadir was 100 cells/μL 
(range, 0–860). The median duration of neutropenia (absolute neutrophil counts <0.5 ×103/μL) was 9 days 
(range 0–33), and 9% of patients did not experience neutropenia. The median platelet nadir was 23 
×103/μL (range, 4–110 ×103). The median duration of thrombocytopenia (platelet counts <20 ×103/μL) was 
0 days (range 0–23), and 62% of patients did not develop thrombocytopenia. 
 
The rates of full donor T-cell chimerism were 76% at day +28, 84% at day +56 and 81% at day +84 in 
evaluable patients. Sixteen patients were excluded for evaluation of the graft rejection outcome: four died 
early (less than 30 days after HCT), eight were transplanted from donors mismatched only in the GVHD 
vector, and four had received planned tandem auto-allo transplants. Four patients died at day 8, 16, 23 and 
29 after HCT. The causes of death were non-relapse mortality (NRM) in two patients and disease 
progression in the other two patients. In one patient who died at day 8 after HCT, hematopoietic recovery 
was not observed. 
 
Among the 43 patients eligible for evaluation of engraftment outcome, 77% and 92% of patients achieved 
full donor T-cell chimerism at days +28 and +56, respectively. Sustained engraftment was observed in 95% 
of evaluable patients 
 
Overall, two patients (one with follicular lymphoma and the other with AML) experienced early graft 
rejection (day 56 and 84, respectively), and there were no late graft rejections. Both patients with early 
graft rejection were successfully transplanted again, one from the same donor with conditioning consisting 
of fludarabine and 4 Gy TBI, and the other patient from an alternative HLA-class I mismatched donor with 
fludarabine, 4 Gy TBI and alemtuzumab (total dose of 10 mg), respectively. 
GVHD 
 
Forty-four of 57 patients (70%), excluding the two rejection patients, developed acute GVHD. Three of the 
44 patients had grade I, 25 grade II, 8 grade III and 8 grade IV GVHD. The cumulative incidences of grades II 
to IV and grades III to IV acute GVHD were 69% and 26%, respectively (Figure 1A). Twenty one patients 
developed chronic GVHD, with a 3-year cumulative incidence of extensive chronic GVHD of 41% (Figure 1B). 
 
Toxicity and non-relapse mortality 
 
Thirty-five patients (59%) experienced at least one non-hematopoietic grade III toxicity, and 20 (34%) had 
at least one non-hematopoietic grade IV toxicity. The most common grade III and IV non-hematopoietic 
toxicities were cardiovascular and pulmonary complications (Table 2). Grade IV cardiac toxicities included 
atrial fibrillation/flutter (n=3), elevated cardiac enzymes suggestive of ischemic events (n=3), pulmonary 
embolism (n=1), septic shock with kidney failure requiring dialysis (n=1), acute myocardial infarction (n=1), 
severe congestive heart failure (n=1), and acute vascular leak syndrome (n=1). Grade IV pulmonary 
toxicities consisted of hypoxia/apnea requiring intubation or pressure support (n=7) and acute respiratory 
distress syndrome (ARDS) (n=2). Grade IV gastrointestinal toxicity consisted of diarrhea or colitis associated 
with GVHD (n=6) or small bowel perforation (unknown etiology) (n=1). 
 
Infection rates were calculated based on infections within the first 100 days post-transplant or until death 
before day 100. The rates of documented viral (including cytomegalovirus reactivation), fungal and 
bacterial infection were 1.5, 0.3, and 2.1 per 100 patient days, respectively, with an overall infection rate of 
3.9 per 100 patient days. 
 
Overall, 26 of 59 patients died from non-relapse causes. The cumulative probabilities of NRM were 22% at 
day 100, 36% at 1 year and 47% at 2 years (Figure 2A). The cumulative incidences of NRM at 2 years for 
patients in CR and those not in CR at the time of transplant were 55% and 37%, respectively. The 
cumulative incidence of NRM for the patients with AML and MDS/AML was 56% at 2 years. Twenty patients 
died of non-relapse causes within 1 year after HCT. Causes of NRM within 1 year after HCT included 
infections associated with GVHD (n=6), multiorgan failure (n=3), infections without GVHD (n=2), GVHD 
(n=2), secondary AML (n=1), ARDS (n=1), bronchiolitis obliterans (n=1), diffuse alveolar damage (n=1), 
myocardial infarction (n=1), leukoencephalopathy (n=1), and congestive heart failure (n=1). Six patients 
died of NRM greater than 1 year after HCT. Causes of late NRM included infections associated with GVHD 
(n=2), infections without GVHD (n=2), cardiac and respiratory failure (n=1), and bronchiolitis obliterans 
organizing pneumonia (n=1). In 3 of the 6 cases, chronic GVHD contributed to the late death. 
  
Relapse and progression free survival 
 
The cumulative probability of relapse/progression was 26% at 2 years (Figure 2A). Progression-free survival 
was 28% at 2 years (Figure 2B). The cumulative incidences of relapse/progression for patients in CR and 
patients not in CR at the time of HCT were 14% and 38% at 2 years, respectively. The cumulative incidence 
of relapse for the patients with AML and MDS/AML (who were all transplanted in CR) was 18% at 2 years. 
The 2-year probabilities of progression-free survival in high and standard/low risk disease were 26% and 
28% (P=0.54), respectively. 
 
 
Survival 
 
Nineteen of 59 patients were alive a median of 24 (range, 2–79) months after transplant. Of the 19, 14 
were in CR, 2 were in PR, 2 had stable disease, and 1 had relapsed. The 2-year overall survivals were 29% 
(Figure 2B). Grade III to IV acute GVHD adversely affected overall survival as time-dependent covariates in a 
Cox regression model (HR 8.35, 95%CI: 3.4–21, P< 0.0001). 
 
The 2-year Kaplan-Meier probabilities of overall survival among patients receiving grafts from one HLA-class 
I antigen mismatched donors (n=48) and those with donors who were mismatched for 2 loci (n=11) were 
26% and 42%, respectively (P=0.35). The 2-year probabilities of overall survival in high and standard/low-
risk disease were 33% and 28%, respectively (P=0.92). Additionally, the 2-year survivals in the groups with 
an HCT-CI score of 0, scores of 1 or 2, and scores of 3 or higher were 46%, 26%, and 20%, respectively 
(P=0.46) (Figure 2C). 
Immune reconstitution 
 
Innate immune cell (NK cells, neutrophils and monocytes) counts recovered within 1 month posttransplant 
(Figure 3A, data on neutrophils and monocytes not shown). DC recovery was slower than that of NK cells, 
neutrophils and monocytes, and more so for the plasmacytoid subset than for the conventional (“myeloid”) 
subset. T cells recovered slowly over several months. B-cell counts were typically still low at 12 months; this 
was true for both naive (surface IgD+) and memory (surface IgD−) B cells (data not shown). CD8+ T cell 
counts reached the normal range between 6 and 12 months, whereas CD4+T-cell counts were still low at 12 
months. Both naive and memory/effector T cells recovered slowly (Figure 3B). CD28− T cells recovered 
faster than CD28+ T cells (Figure 3B). 
 DISCUSSION 
 
In studies of patients who receive myeloablative conditioning and unrelated marrow grafts, the incidence 
of graft rejection was higher among patients given grafts mismatched for one or more class I HLA antigens 
[5]. We sought to determine whether graft rejection was increased when class I HLA-mismatched grafts 
were transplanted after nonmyeloablative conditioning and found that sustained donor engraftment was 
observed in 95% of recipients. Although initially designed as a dose escalation trial of alemtuzumab 
according to the number of patients experiencing graft rejection, the dose-escalation rule was never 
activated. Thus the combination of fludarabine and 2 Gy TBI, followed by a post-transplant combination of 
MMF given three times a day (TID) and CSP, was sufficient to ensure a high rate of sustained full donor T-
cell chimerism and engraftment even with HLA-class I mismatched grafts. 
 
We previously had used 15 mg/kg MMF BID administrated from day 0 to day 40 with taper through day 96 
in combination with CSP as GVHD prophylaxis after nonmyeloablative HLA-matched unrelated donor HCT. 
However, a high graft rejection rate of 21% was observed. By increasing the dosing of MMF to 15 mg/kg TID 
(because of the short half-life (t½) of only 3 hours of the active metabolite of MMF) [7] and using only G-
PBSC as a stem cell source, we successfully reduced the rejection rate to 5 % in nonmyeloablative HCT from 
HLA-matched unrelated donors [32]. Therefore, in the current study we used MMF 15 mg/kg TID and 
extended the duration of MMF given until day 100 for the HLA-mismatched setting. As a result, sustained 
engraftment was observed in 95% of evaluable patients without the use of alemtuzumab. 
 
We were unable to detect any enhancement of graft-versus-tumor effects with the use of HLA-mismatched 
unrelated grafts. Observed cumulative probabilities of relapse/progression of 22% at 1 year and 36% at 2 
years were very similar to our previous HLA-matched unrelated HCT data (26% at 1 year and 31% at 2 
years) [32]. If limited to patients not in CR at HCT, the CR rate in this study [8 of 30 (27%)] was lower rather 
than 48% of the previous our study. 
 
An association between HLA-class I mismatches and a high incidence of GVHD has been described in 
recipients of ablative conditioning regimens followed by unrelated donor HCT [33–35]. Previous studies 
reported that the cumulative incidences of grades II to IV acute GVHD varied from 43% to 74% after 
myeloablative HCT with HLA-matched unrelated marrow and 63% to 80% after myeloablative HCT with 
HLA-one antigen mismatched unrelated marrow [36–39]. Chronic GVHD was observed in more than 55% of 
patients after myeloablative HCT with HLA-matched unrelated marrow and in 70% of patients after 
myeloablative HCT with HLA-one antigen mismatched unrelated marrow [21,36–39]. In a previous study 
using the same nonmyeloablative conditioning regimen (fludarabine and 2 Gy TBI), 103 patients received 
either 10/10 HLA-matched (n=93) or single HLA class I allele-level mismatched (single each; n=10) unrelated 
donor HCT. In that study, we reported cumulative incidences of grades II to IV acute and chronic extensive 
GVHD were 53% and 56%, respectively [32]. Interestingly, the observed 41% incidence of chronic extensive 
GVHD in the current study is comparable to or less than that observed in the HLA-matched unrelated 
setting. The prolonged CSP and MMF administration in this study may have contributed to the similar 
incidence of chronic GVHD. On the other hand, the observed 69% rate of grades II to IV acute GVHD is 
higher than that seen in the HLA-matched unrelated setting [32]. The cumulative probability of NRM of 47% 
at 2 years in the current study is also higher than that seen in the HLA-matched unrelated setting. 
Additionally, in the current study acute GVHD contributed to death in 9 of 26 non-relapse deaths (35%), 
and 6 of 7 (86%) grade IV gastrointestinal episodes were associated with gut GVHD which directly or 
indirectly caused mortality. 
 
As might be expected, there was concern that the prolonged CSP and MMF administration in the present 
protocol caused an increased risk of infection. Indeed, the incidence of infection was increased compared 
to our previous results in unrelated HCT (the documented rates per 100 patients days of viral, fungal, and 
bacterial infection were 0.86, 0.26, and 1.05, respectively, in the previous study [32]). In 12 of 26 (46%) 
patients, the causes of NRM were associated with infection. 
 
Since excess immunosuppression can lead to high rates of relapse and infection due to delayed immune 
reconstitution, an optimal prophylactic regimen for GVHD in HLA-mismatched or unrelated HCT has been 
explored by other investigators. Alemtuzumab (total 50, 100 mg/person or 1.2 mg/kg) has been applied in 
HLA haploidentical related, and HLA-matched and mismatched unrelated HCT [40–43]. Some investigators 
reported that alemtuzumab-containing regimens were highly effective in preventing chronic as well as 
acute GVHD without an increased risk of relapse [40,41]. However, high relapse rates, particularly in 
patients with active disease at HCT (5 of 8 patients [63%]) [42] and high infection rates (serious infective 
complication 62.2%) [43] due to a delay in immune reconstitution were also reported. Furthermore, in a 
recent publication, we reported that HLA-haploidentical nonmyeloablative related HCT with high-dose 
posttransplantation cyclophosphamide showed an acceptable sustained engraftment rate of more than 
95% and better control of acute GVHD (34% for grades II–IV and 6% for grades II–IV 6%) without increased 
severe infection. However, a relatively high relapse rate of 51% at 1 year was seen [44]. In our previous 
retrospective study, extensive chronic GVHD but not grade II to IV acute GVHD was significantly associated 
with a decreased risk of relapse or progression without increased NRM [45]. These data indicate that an 
intensified prophylaxis of acute GVHD but not chronic GVHD by an additional immunosuppressive agent 
such as low-dose alemtuzumab [46] or sirolimus [47] may be a reasonable strategy to improve outcomes. 
 
The observed overall survivals in all the three groups stratified by HCT-CI score were inferior to recipients of 
HLA-matched related and/or unrelated HCT. These data suggested that HLA-class I disparity could be 
another independent outcome factor in the nonmyeloablative setting. 
 
Immune reconstitution was similar to that after HLA-matched unrelated donor nonmyeloablative HCT [48], 
with the exception of slower recovery of CD8+ T cells and B cells. Both naive and memory/effector CD8+ T 
cells recovered slowly, suggesting both reduced thymopoiesis as well as reduced peripheral expansion, 
possibly due to the fact that many patients had GVHD (clinical or subclinical) and were treated with 
prolonged immunosuppression drugs. The slow recovery of B cells may also be due to the fact that many 
patients had GVHD, as GVHD and/or its treatment hamper B-lymphopoiesis [49,50]. The slow recovery of 
CD8+ T cells and B cells might have contributed to the relatively high infection rates. 
 
In conclusion, this study demonstrated the feasibility of nonmyeloablative HCT from HLA-class I 
mismatched donors using fludarabine and low-dose TBI conditioning. While almost 30% of patients 
experienced long-term survival with this approach, there was a high incidence of acute GVHD and NRM 
decreased survival compared to fully HLA-matched unrelated patients. Future studies of more intense early 
prophylaxis of GVHD in this HLA-class I mismatched setting may decrease severe acute GVHD and improve 
survival. 
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